"Performance" GSK's third-quarter performance exceeded expectations and raised the full-year guidance, with the stock price rising by 6%
GlaxoSmithKline (GSK.US) saw its stock price rise 6% in the early trading session on Wednesday, as its third-quarter performance exceeded expectations and it raised its outlook guidance.
The company's earnings per share for the third quarter were approximately $0.73, higher than the market expectation of $0.61; sales were $11.35 billion, also surpassing the expected $10.93 billion. The company raised its annual guidance, now expecting sales to grow by 6% to 7%, up from the previous estimate of 3% to 5%. Additionally, the company anticipates core earnings per share to grow by 10% to 12%, higher than the previous forecast of 6% to 8%
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments